C-Path launches Type 1 Diabetes (T1D) Consortium
C-Path collaborates with FDA’s CDER and FNIH’s Biomarker Consortium in drafting a “Framework for Defining Evidentiary Criteria for Biomarker Qualification”
C‐Path receives approval from the European Medicines Agency (EMA) for imaging biomarker as a qualified measure to select patients with early stage cognitive impairment for Alzheimer’s disease clinical trials.
With support and funding from the Polycystic Kidney Disease Foundation, C‐Path launches Polycystic Kidney Disease Outcome Consortium (PKDOC).
C‐Path launches Critical Path to TB Drug Regimens (CPTR).
C‐Path launches Coalition Against Major Diseases (CAMD) as a consortium with pharmaceutical companies, patient groups, FDA and NIH to address clinical trial needs in neurological diseases.
Arizona’s Governor Janet Napolitano honors C‐Path with an “Arizona Innovation Award” to recognize its groundbreaking approach to speeding the development of safe, innovative medicines and medical devices.
President George W. Bush signs bill that authorizes FDA to create “Critical Path Public/Private Partnerships.” The first (and most successful) of these is the collaboration between the FDA and C‐Path.
C‐Path hosts ribbon‐cutting ceremony at the Library of Congress to officially announce opening of its Rockville, Maryland office.
C‐Path hosts Tucson ribbon‐cutting ceremony to officially launch institute.
C‐Path begins first fiscal year with six full‐time employees.
State of Arizona awards C-Path a planning grant. C-Path files articles of non-profit incorporation.